AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. MRVL

Go back to AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection
AbbVie (NYSE: ABBV) Delayed: 227.73 +2.96 (1.32%)
Previous Close $224.77    52 Week High $68.12 
Open $227.50    52 Week Low $50.71 
Day High $228.40    P/E 49.40 
Day Low $224.32    EPS $4.61 
Volume 4,086,391